Fig. 1
From: Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
Development pathways for originator biologics and biosimilars: a different way of thinking. Adapted from Kozlowski et al., 2012. PD: pharmacodynamics, PK: pharmacokinetics